ANAPTYSBIO, INC. Defined Contribution Plan, Employer Matching Contribution, Percent of Match
ANAPTYSBIO, INC. (ANAB) reported Defined Contribution Plan, Employer Matching Contribution, Percent of Match of 100.00% for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Compensation Related Costs › Defined Contribution Plan
us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch · last filed 2026-09-21
- ANAPTYSBIO, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2025 was 100.00%, a 0.00% change from fiscal 2024.
- ANAPTYSBIO, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2024 was 100.00%, a 0.00% change from fiscal 2023.
- ANAPTYSBIO, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2023 was 100.00%, a 0.00% change from fiscal 2022.
- ANAPTYSBIO, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2022 was 100.00%, a 100.00% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 6 month | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 12 month | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 12 month as first filed |
|---|---|---|---|
| 2026-06-30 | 100.00% 10-KT · filed 2026-09-21 | ||
| 2025-12-31 | 100.00% 10-KT · filed 2026-09-21 | ||
| 2024-12-31 | 100.00% 10-KT · filed 2026-09-21 | ||
| 2023-12-31 | 100.00% 10-K · filed 2026-03-03 | ||
| 2022-12-31 | 100.00% 10-K · filed 2025-02-27 | ||
| 2021-12-31 | 50.00% 10-K · filed 2023-03-01 | 100.00% 10-K · filed 2022-03-07 | |
| 2020-12-31 | 50.00% 10-K · filed 2023-03-01 | ||
| 2019-12-31 | 50.00% 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |